Objectives: Because the central nervous system (CNS) is the second most frequently affected organ in mitochondrial disorders (MIDs) and since paediatric MIDs are increasingly recognised, it is important to know about the morphological CNS abnormalities on imaging in these patients. This review aims at summarising and discussing current knowledge and recent advances concerning CNS imaging abnormalities in paediatric MIDs. Methods: A systematic literature review was conducted. Results: The most relevant CNS abnormalities in paediatric MIDs on imaging include white and grey matter lesions, strokelike lesions as the morphological equivalent of stroke-like episodes, cerebral atrophy, calcifications, optic atrophy, and lactacidosis. Because these CNS lesions may be seen with or without clinical manifestations, it is important to screen all MID patients for cerebral involvement. Some of these lesions may remain unchanged for years whereas others may be dynamic, either in the sense of progression or regression. Typical dynamic lesions are stroke-like lesions and grey matter lesions. Clinically relevant imaging techniques for visualisation of CNS abnormalities in paediatric MIDs are computed tomography, magnetic resonance (MR) imaging, MR spectroscopy, single-photon emission computed tomography, positron-emission tomography, and angiography. Conclusions: CNS imaging in paediatric MIDs is important for diagnosing and monitoring CNS involvement. It also contributes to the understanding of the underlying pathomechanisms that lead to CNS involvement in MIDs.
Introduction
Mitochondrial disorders (MIDs) are usually multisystem diseases (syndromes) affecting the central and peripheral nervous system (CNS), eyes, ears, endocrine organs, heart, lungs, gastrointestinal tract, kidneys, bones, joints, blood, skin, or arteries, alone or in variable combination. 1 Depending on the combination of organ involvement, around 50 specific syndromes have been defined, which are tagged with acronyms (e.g. mitochondrial encephalopathy lactic acidosis and stroke-like episodes (MELAS), myoclonic epilepsy with ragged-red fibres (MERRF) etc). Contrary to these specific MIDs, the vast majority of MIDs present as non-specific mitochondrial multi-organ disorder syndromes (MIMODSs). 2 Onset of clinical manifestations ranges from birth to senescence and the disease course is usually slowly or rarely rapidly progressive. The second most frequently affected organ after the skeletal muscle in MIDs is the CNS. 3 In the majority of cases specific abnormalities can be found on imaging in the case of CNS involvement in a patient with MID. This review aims at summarising and discussing current knowledge and recent advances about imaging abnormalities, imaging modalities, and dynamics of imaging changes in paediatric MIDs with CNS 
Definition and pathophysiology
Generally, MIDs are either due to mutations in the mitochondrial DNA (mtDNA) or the nuclear DNA (nDNA). mtDNA mutations usually affect one of the 37 mtDNA-located genes or rarely non-coding mtDNA regions (e.g. D-loop). Of the approximately 1500 nDNA-located genes associated with mitochondrial functions, approximately 200 are currently known. 4 These mutations may lead to absent or abnormal structural proteins, such as receptors, channels, or transporters. 1 Dysfunction of these proteins may lead to abnormal mitochondrial metabolism (e.g. respiratory chain, beta-oxidation), signalling, morphology, transport, bioenergetics, or mtDNA replication. Among the MIDs with onset in infancy, childhood, or adolescence (paediatric MIDs), approximately 75% are due to mutations in nDNA-located genes. Risk factors for exacerbation, progression, or worsening of an MID are drugs, infections, food, surgery, anaesthesia, and any type of stress.
Epidemiology
Since MIDs are a heterogeneous group of disorders and since MIDs are still diagnosed rarely or with delay, exact figures about the frequency of MIDs are not often available and frequently rely on estimations. The estimated prevalence of specific MIDs is 1:4000 but only 1:7500 are diagnosed correctly. 4 The estimated prevalence of MIMODS is 1:400. 5 
Overall costs to society
As with all disorders that are not diagnosed correctly, costs for the management of MIDs may increase with the duration of misdiagnosing. Thus, early correct diagnosis may lower costs for the diagnostic work-up. A correct diagnosis may also lower costs for the treatment since it will be more specific if the diagnosis is known.
Goals of imaging
Cerebral imaging in paediatric MIDs aims at identifying morphological and functional cerebral abnormalities and at correlating imaging abnormalities with the clinical presentation.
Methods
Data for this review were identified by searches of MEDLINE for references of relevant articles. Search terms used for this database were 'mitochondrial', 'mitochondrion', 'respiratory chain', 'mtDNA', 'nDNA', and all acronyms in combination with 'cerebral', 'imaging', 'central nervous system', 'brain', 'cerebral computed tomography', 'magnetic resonance imaging', singlephoton emission tomography ('SPECT'), positronemission tomography ('PET'), 'paediatric', 'infancy', 'childhood' and 'adolescence'. Results of the search were screened for potentially relevant studies by application of inclusion and exclusion criteria for the full texts of the relevant studies. Included were randomised controlled trials, observational studies with controls, case series, and case reports. Only original articles about humans published between 1966 and 2017 were included. Reviews, editorials, and letters were not included. Reference lists of retrieved studies were checked for reports of additional studies.
Results

Literature selected for review
By searching the literature according to the criteria mentioned above, the number of hits achieved was 373. By filtering these results by application of inclusion and exclusion criteria, the number of hits was reduced to 189. After studying the abstracts, 143 papers were selected for detailed study but only 133 relevant articles were accessible as full papers and thus included in the specific discussion.
Specific and non-specific paediatric MIDs
There are MIDs which present with early onset in the majority of cases and MIDs which can only occasionally be classified as paediatric (Table 1) . MIDs with obligatory onset in infancy, childhood or adolescence in the majority of cases include Leigh syndrome (LS), AlpersHuttenlocher syndrome, chronic progressive external ophthalmoplegia (CPEO), Kearns-Sayre syndrome (KSS), Pearson syndrome, and mitochondrial depletion syndrome (MDS) ( Table 1) . MIDs with occasional onset in infancy, childhood or adolescence include mitochondrial neuro-gastrointestinal encephalomyopathy, neurogenic muscle weakness, ataxia, and retinitis pigmentosa (NARP) syndrome, MELAS, MERRF, Leber's hereditary optic neuropathy (LHON), Wolfram-syndrome, familial bilateral striatal necrosis, and MIMODS due to POLG1 mutations (Table 1 ).
Imaging techniques applied
Imaging techniques applied to document CNS abnormalities in paediatric MIDs include ultrasound investigations, cerebral computed tomography (CCT), cerebral magnetic resonance imaging (cMRI), cerebral magnetic resonance spectroscopy (MRS), SPECT, PET with or without CT (PET-CT), and conventional or MR angiography to visualise cerebral vessels. Owing to their different availability and sensitivity and specificity to detect CNS abnormalities, some of these techniques for visualising CNS abnormalities are more important in the daily routine than others. 34 MRI may show atrophy, cytotoxic or vasogenic oedema, hypomyelination, demyelination, macro-or micro-bleedings, optic atrophy, pituitary adenoma, leucoencephalopathy, pituitary adenoma, or empty sella.
MRS.
MRS is a non-invasive, ionising-radiation-free technique to study metabolic changes in the brain or other tissues. 35 MRS uses signals from hydrogen, carbon, or phosphorus protons (H-MRS, C-MRS, P-MRS) to determine the relative concentrations of various metabolites. 35 H-MRS is the method of choice to measure cerebral metabolites non-invasively. Metabolites that can be quantified by H-MRS include N-acetyl-aspartate (reduction indicates neuronal loss), choline (increase indicates demyelination or malignancy), creatine (decrease indicates cell death), lipids (increase indicates necrosis), lactate (increase indicates glycolysis, ischaemia, hypoxia, or a mitochondrial defect), myoinositol (increase indicates dementia, human immunodeficiency virus), and glutamate (increase indicates hyperammonaemia or hepatic encephalopathy). 35 Concerning the sample volume, two techniques are applied: single-voxel MRS and multi-voxel MRS. Multi-voxel MRS allows better spatial resolution than single-voxel MRS. In single-voxel MRS the signal is received from a volume limited to a single voxel, whereas in multi-voxel MRS a large volume is divided into multiple smaller voxels, with each giving rise to a spectrum simultaneously. 7.3.5 SPECT. SPECT is a nuclear medicine tomographic imaging technique using gamma rays. SPECT is able to provide three-dimensional (3D) information. 37 Sources of gamma rays are various types of radioactive tracers which are usually injected. Tracers used in mitochondrial medicine include hydrogen ( T) or of densities of receptors, transporters, or structural proteins. Accordingly, SPECT is helpful to confirm the diagnosis of mitochondrial Parkinsonism, and to exclude various differentials of mitochondrial dementia, such as Alzheimer disease, frontoemporal dementia, progressive supranuclear palsy, Pick's disease, or multisystem atrophy.
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PET (PET-CT).
PET is a nuclear medicine functional imaging technique used to assess metabolic processes. As with SPECT, the technique relies on the indirect emission of gamma rays by a positron-emitting tracer, which is introduced into the body via a biologically active molecule. PET provides 3D information by the aid of a CT X-ray scan performed during the same session with the same machine. 39 In mitochondrial medicine, PET is useful to demonstrate cerebral hypoor hypermetabolism by application of the tracer fludeoxyglucose. 
Classification of cerebral lesions on imaging
Lesions on cerebral imaging in paediatric MIDs may be classified according to various criteria. According to the consequence of the lesions, lesions may be classified as structural or functional. According to the frequency, they may be classified as frequent or rare. According to the influence on the phenotype, they may be categorised as dominant or non-dominant. According to the technique applied they may be categorised as visible on CCT, cMRI, angiography, MRS, SPECT, or PET. Lesions on cerebral imaging in MIDs may also be categorised into those that accompany clinical manifestations and those that do not.
Typical cerebral lesions on imaging
7.5.1 WMLs 7.5.1.1 Presentation. The most frequent CNS abnormality on imaging in paediatric MIDs are WMLs. They present as hyperintensity on T2-weighted or fluidattenuated inversion recovery (FLAIR) images on MRI 40, 41 or as hypodensities on CCT. WMLs in MIDs may be focal, disseminated, confluent, subcortical, or periventricular, depending on the degree and location in the brain. 42 Occasionally, WMLs may also be found in the basal ganglia (Nucleus caudatus, putamen, globus pallidus), midbrain, pons, or cerebellum. 43, 44 Sometimes WMLs are found in watershed regions. 45 Occasionally, WMLs are accompanied by cystic lesions within the white matter. 21 WMLs may be seen with or without grey matter lesions (GMLs) or other cerebral manifestations of an MID with CNS involvement. WMLs have been described in patients with MELAS, 46 mitochondrial neuro-gastrointestinal encephalomyopathy, 19 leucoencephalopathy with brainstem and spinal cord involvement and lactic acidosis (LBSL) due to DARS2 mutations, 26 and several MIMODSs. 53, 54 Particularly in children with MIMODS due to POLG1 mutations WMLs have been reported. 55 WMLs may occur not only in the cerebrum but also in the spinal cord such as in LBSL or hypomyelination with brainstem and spinal cord involvement and limb spasticity (HBSL) due to DARS mutations. 26 In HBSL particularly in the dorsal columns and the lateral corticospinal tracts are affected. 26 Periventricular WMLs were reported in infants carrying IBA57 mutations. 56 WMLs in LHON may mimic lesions typically found in multiple sclerosis, which is why these patients are frequently misdiagnosed and mistreated. An increased blood-brain barrier permeability has been speculated to cause WMLs in mitochondrial neurogastrointestinal encephalomyopathy. 42 There is no general correlation between the extent of WMLs and the phenotype but in individual patients cerebral functions deteriorate with extension of the WMLs. 46 Generally, WMLs of unknown aetiology in a patient with multisystem disease should raise the suspicion of an MID. 46 
GMLs. GMLs most frequently occur in LS.
Symmetric necrosis of the basal ganglia, thalami, diencephalon, cerebellum, brainstem, or the spinal cord, showing up as T2-hyperintensities, are the hallmark of LS and Leigh-like syndrome on CNS imaging. 49, [58] [59] [60] [61] [62] In LS, GMLs are typically progressive in terms of extension and density. Usually, the basal ganglia are affected before the brainstem. 58 After the putamen, globi pallidi, caudate nuclei, or the thalami are affected, the substantia nigra, peri-aqueductal grey matter, inferior colliculi, inferior olivary nuclei, or reticular formation may become additionally involved. 58 Histologically, GMLs in LS present as spongiform degeneration with astrocytosis, microglial reaction, vacuolation, vascular proliferation, and macrophage infiltration within the basal, ganglia, brainstem, and spinal cord. 63 In the advanced stages of LS, WMLs additionally occur. 58 There is no correlation between GMLs and the clinical course or age at onset. 58 GMLs may be accompanied by WMLs in some patients 64 and may spontaneously regress. 64 Some patients may show iron deposition within the basal ganglia and others may develop bilateral basal ganglia degeneration, like in LHON. 32 In a 15-year-old female and a 6-year-old female, both carrying a PET117 mutation, T2-weighted MRI images revealed focal, symmetric hyperintensities of the brainstem. 65 Bilateral symmetric involvement of the deep grey matter was found in up to 50% of patients with MIDs, but most frequently in LS. 34 GMLs typical for LS have also been reported in 3-methylglutaconic aciduria with deafness, encephalopathy and Leigh-like syndrome. 66 Hyperintensities of the putamen and the cortex have been reported in patients with primary coenzyme-Qdeficiency. 67 T2-hyperintensities of the thalamus, inferior olives, and the cerebellum were found in patients with sensory ataxic neuropathy, dysarthria and ophthalmoplegia. 68 In a study of 15 patients with childhood-to adulthood-onset mitochondrial membrane protein-associated neurodegeneration due to C19orf12 gene mutations, MRI revealed bilateral T2-hyperintensities of the globus pallidus and substantia nigra without an eye-of-the-tiger sign but with frequent streaking of the medial medullary lamina between the external and internal parts of the globus pallidus. 29 Visualisation of symmetric necrosis of the thalami, basal ganglia, diencephalon, or brainstem in patients with LS or Leigh-like syndrome (subacute necrotising encephalomyelitis) on CCT is limited. 32 7.5.3 SLLs. SLLs, the imaging correlate of strokelike episodes (SLEs), are a hallmark of MELAS but they may occur in other specific or non-specific MIDs as well. 69 These include MERRF, KSS, LS, LHON, CPEO, Saguenay-Lac-St-Jean cytochrome oxidase deficiency, propionyl-CoA carboxylase deficiency, POLG1-related disorders, triple-H syndrome, mitochondrial spinocerebellar ataxia (SCA) due to twinkle mutations, and MIMODS. 69 SLLs manifest clinically as focal motor or sensory deficits, including hemiparesis, hemiataxia, hemianopsia, bilateral visual loss, or hemi-hypoesthesia. 70 SLLs typically show a dynamic course during days, weeks, or months, resulting in complete remission of the clinical manifestations or slow progression after each episode. 71 Since clinical manifestations of SLLs can mimic cerebral ischaemia, they may easily be mixed up with ischaemic stroke.
7.5.3.1 Presentation on MRI 7.5.3.1.1 Acute stage. In the acute stage SLLs present as hyperintensities on T2/FLAIR and diffusion-weighted imaging 34 and as iso-or hyperintensities on apparent diffusion coefficient maps. [72] [73] [74] [75] [76] [77] [78] Some studies also reported restricted diffusion within SLLs. 75, 76, 79, 80 Diffusion-weighted imaging is regarded as more sensitive than T2-weighted images to demonstrate SLLs. 46 On T1-weighted images acute or subacute SLLs show up as slight hypointensities. SPECT studies and perfusion-weighted imaging may show focal hyperperfusion. 81 Hyperperfusion during the acute stage of an SLL in MELAS has also been reported by others. 82 SLLs may frequently recur. 83 On CCT scans, acute SLLs show up as hypodensities with mass effect and effacement of the sulci on the surface of the homolateral hemisphere but visualisation of SLLs on CCT is generally limited. 84 Acute SLLs on imaging should prompt treating physicians to apply appropriate treatment (e.g. antiepileptic drugs, nitric oxide precursors).
7.5.3.1.2 Chronic stage. In the chronic stage, SLLs present as hypo-, iso-, or hyperintensity on T2/FLAIR, as hyperintensity or isointensity on diffusion-weighted imaging, as hypo-or isointensity on apparent diffusion coefficient, and as hypoperfusion on perfusionweighted imaging (Table 2 ). In the chronic stage, SLLs may be intermingled with cystic lesions. SLLs can occur in all cerebral regions but most frequently in the occipital, parietal, or temporal lobe. [72] [73] [74] 85, 86 Rarely, the deep grey matter may be additionally involved. Typically, SLLs expand and spread into neighbouring areas within the first days after onset. 87, 88 SLLs may either persist during years or may disappear after weeks or months. In the chronic stage of a SLL cortical atrophy may develop. 89 Hyperperfusion on perfusion-weighted imaging may already be present weeks prior to the clinical onset of an SLL. 90 
Presentation on MRS.
H-MRS typically shows increased lactate and reduced N-acetyl-aspartate, glutamate, myo-inositol, cholin, or creatine concentrations within SLLs. 91, 92 This pattern can be detected in all MIDs which accompany SLLs. Similar but less prominent alterations can be found in the grey matter. 92 
Presentation on SPECT.
In the acute stage SLLs in MELAS patients show up as increased cerebral blood flow (hyperperfusion) on 99mTc-hexamethylpropylene amine oxime SPECT. 81, 93 Diffuse hyperperfusion, most pronounced within SLLs, may also be found even weeks after an SLE. In CPEO, on the contrary, the cerebral blood flow may be decreased. 81, 94 Irrespective of whether patients had suffered from SLEs, SPECT may show multiple areas of asymmetrical hypoperfusion, particularly in the posterior or lateral cerebral regions, including the temporal lobes. Crossed-cerebellar diaschisis has also been reported. 94 7.5.3.4 Pathogenesis. The pathogenesis of SLLs is unknown. Possible hypotheses to explain these phenomena include mitochondrial angiopathy, mitochondrial cytopathy, or neuron-astrocyte uncoupling. 95 Mitochondrial vasculopathy may lead to vasogenic oedema, which does not conform to a specific vascular territory, occurs in the white and grey matter, and spreads or regresses over weeks, months, or years. 81 Owing to the non-vascular distribution of SLLs, however, the vascular hypothesis is rather unlikely. An additional argument against the vascular hypothesis is that the cerebral blood flow after an SLE is well preserved whereas oxygen metabolism is decreased. 96 7.5.3.5 Outcome of SLLs. The end stage of SLLs is variable. There may be complete remission or a persistent imaging abnormality. Persistent imaging abnormalities include WMLs, atrophy, laminar cortical necrosis (LCN), 81 or the black toenail sign. 19 LCN is characterised by permanent, focal or diffuse cortical high signals on T1/FLAIR images, which follow the gyral anatomy of the cerebral cortex. 97 Most frequently LCN is found in MELAS but has been also described in patients with LS and non-mitochondrial conditions, such as hypoxia, ischaemia, hypoglycaemia, hepatopathy due to hyperammonaemia, ischaemic stroke, Moyamoya syndrome, meningoencephalitis, shakenbaby syndrome, epileptic state, citrullinemia, or posterior reversible encephalopathy syndrome. Clinical manifestations of LCN include spasticity, weakness, decreased intellectual capacity, aphasia, hemianopsia, sensory disturbances, or epilepsy. 97 LCN may lead to cortical atrophy. The black toenail sign is a phenomenon occurring in MELAS if SLEs ultimately lead to gyral necrosis affecting the cortex or the juxtacortical white matter. 19 The neuroimaging correlate is partial gyral signal suppression on T2/FLAIR sequences that resembles black toenails. 19 In a retrospective study of 124 MRI examinations from 14 MELAS patients with a mean age of 16 years, gyral necrosis was found in six patients. 19 Necrotic lesions varied in maximal diameter from 4 to 25 mm. The cumulative number of necrotic lesions correlated with disease duration. 19 7.5.4 Atrophy/hypertrophy. Atrophy of the brain is a common finding on CNS imaging in MIDs and may be categorised as focal or diffuse, cortical or subcortical, supratentorial or infratentorial, or as primary or secondary following another cerebral lesion. Atrophy may be the sole imaging finding in up to one-quarter of MIDs. 34 Diffuse cortical atrophy occurs in up to one-third of patients with encephalomyopathy. 42 Cortical atrophy may also develop in the chronic stage of LCN. 89 In the majority of the cases cortical atrophy is associated with cognitive impairment. 98, 99 Focal atrophy may concern various cerebral regions. Predominant cerebellar atrophy with or without cerebral atrophy has been reported in some patients with LS. 41, 100 Isolated cerebellar atrophy has been particularly described in KSS, CPEO, MERRF, NARP, LBSL, LS, pontocerebellar hypoplasia type-6, AlpersHuttenlocher syndrome, and MIMODS. 34, 42 Atrophy of the corpus callosum, the caudate nucleus, the basal ganglia, or the parietal, temporal, or frontal lobe are also typical representations of focal atrophy. Focal atrophy of the corpus callosum, pons or the cerebellum has been reported in patients with pontocerebellar hypoplasia type-6 due to mutations in the RARS2 gene. 101 In a mouse model of pontocerebellar hypoplasia due to mutations in the SLC25A46 gene, animals developed optic atrophy in addition to cerebellar hypoplasia. 102 The degree of atrophy may increase with progression of the disease. In a 7-year-old male with MDS due to a mutation in the SUCLA2 gene, MRI of the cerebrum showed atrophy of the caudate nucleus and the putamen. 11 In a girl with NARP syndrome due to the mutation m.8729G>A resulting in complex-I and complex-IV deficiency, and onset in childhood, cerebral MRI showed marked atrophy of the cerebellum and the brainstem. 18 In patients carrying mutations in the AIFM1 gene, which encodes a mitochondrial flavoprotein involved in NADH oxidoreductase activity and apoptosis, isolated atrophy of the cerebellar vermis has been reported. 103 Cerebellar ataxia in these patients responded favourably to high-dose riboflavin. 104 In a study of 20 patients with CPEO due to single or multiple mtDNA deletions, cerebellar atrophy was found in all of them. 104 Diffuse or focal atrophy of the supratentorial cortex has been reported in paediatric patients with MIMODS. 53 Atrophy of the vermis and the cerebellar hemispheres has also been reported in patients with LHON plus (dilated cardiomyopathy and ataxia). 105 Marked cerebellar atrophy may also be a CNS feature of primary coenzyme-Q deficiency. Atrophy or agenesis of the corpus callosum is a prominent imaging feature in a number of specific and non-specific MIDs. 107 Symmetrical hypertrophy of the olives has been reported in a patient with sensory ataxic neuropathy, dysarthria, and ophthalmoplegia syndrome due to a POLG1 mutation. 108 Atrophy can also be visualised by CCT, such as atrophy of the cerebellum in MELAS. 109, 110 7.5.5 Calcifications. Calcifications of the cerebral parenchyma or the cerebral arteries have been repeatedly reported in paediatric MIDs. 18 Calcifications may occur uni-or bilaterally and can be most elegantly visualised by CCT. 111 MRI is less apt to visualise cerebral calcifications. Most frequently CNS calcifications have been described in the basal ganglia, 18 and less frequently in the dentate nuclei or the cerebellum. 110 Basal ganglia calcification is not restricted to a particular MID but may occur with most of the known syndromes, most frequently, however, with MELAS and KSS. 99, 110, 112 Bilateral symmetric calcifications have also been found in a girl with NARP syndrome due to the mutation m.8729G>A resulting in complex-I and complex-IV deficiency. 18 In an infantile male and female sibling with combined complex-I/IV defect, ultrasonography of the brain revealed multifocal cerebral calcifications in one of them. 31 The most common locations of calcifications in MELAS are the caudate nucleus, putamen, globus pallidus, and the thalamus. 31 7.5.6 Optic atrophy. Atrophy of the optic nerves is frequently mentioned in paediatric MID patients but only rarely visualised or reported. Coronal planes on MRI are the most suitable modality to visualise optic atrophy. In a study of three affected individuals carrying a C12orf65 mutation, early-onset optic atrophy was one of the dominant features. 107 Optic atrophy has been repeatedly reported in Wolfram (DIDMOAD) syndrome. 113 Additionally, optic atrophy is the dominant phenotypic feature of LHON, ADOA and AROA. 114 In a mouse model of pontocerebellar hypoplasia due to mutations in the SLC25A4 gene, optic atrophy was reported. 102 Optic atrophy has also been reported in patients with infantile-onset spinocerebellar ataxia.
14 There are also a number of other specific and non-specific MIDs in which optic atrophy was either a dominant or non-dominant feature of the phenotype, known as optic atrophy spectrum disorders. 114 7.5.7 Abnormal concentrations of cerebral metabolites on MRS. A frequent cerebral abnormality in paediatric MIDs is elevated cerebral lactate. 115 It can be confirmed by invasive or non-invasive measurement of the lactate levels in the cerebrospinal fluid. Noninvasively, lactate can be determined by application of H-MRS. 116 Depending on the voxel placement, a double lactate peak may be seen with the spectra if lactate is elevated. Lactate peaks may be recognised in areas with and without abnormalities on imaging. 118 Lactic acidosis may precede or accompany SLEs but may also occur in the absence of SLEs. 46 Elevated lactate is the most frequent abnormality on H-MRS in paediatric and adult MIDs. 46, 49, 75, 78, [117] [118] [119] [120] [121] [122] Cerebral lactic acidosis is usually associated with severe neurologic impairment. 123 Cerebral lactate may be elevated not only in MIDs but also in cerebral infections or malignancies. MIDs with lactate peaks on MRS include LS, MELAS, LBSL, EARS2-assocaited MID, RRM2B-related MID, OPA1-related MID, VARS2-associated encephalocardiomyopathy, and MIMODS. Ventricular accumulation of lactate upon H-MRS was also reported in a study of six LHON patients. 124 A disadvantage of single-voxel H-MRS is that mitochondrial dysfunction often has a patchy, regional distribution, which is why lactacidosis may be found in some areas but not in others. 42 In areas without a lesion on imaging, the cholin peak, creatine peak, or N-acetylaspartate peak may be reduced. 53, 118 In patients with LS increased concentrations of choline were found in the white matter and attributed to ongoing demyelination. 120 In the absence of a structural abnormality on cerebral MRI, sampling of the basal ganglia for MRS is recommended. 42 7.6 Rare CNS abnormalities 7.6.1 Ischaemic stroke. Ischaemic stroke is a rare manifestation of MID and may occur if there is primary or secondary mitochondrial vasculopathy of the large extra-or intracranial arteries. Secondary mitochondrial vasculopathy may be due to mitochondrial diabetes, arterial hypertension, or hyperlipidaemia, or cardiac involvement, such as atrial fibrillation, dilative or hypertrophic cardiomyopathy, or left ventricular hypertrabeculation/noncompaction. Mitochondrial microangiopathy may result from primary or secondary affection of the endothelium or the vascular smooth muscle cells by the MID or classical cerebrovascular risk factors resulting in stenosis or occlusion of small arteries, arterioles, or capillaries, and thus lacunar ischaemic stroke. Stroke from macroangiopathy may be due to stenosis or dissection of the large intracerebral arteries. 80 Moyamoya disease may be another pathomechanism of ischaemic stroke in MIDs. 125 Moyamoya disease develops in case of spontaneous occlusion of the supraclinoidal internal carotid arteries and the proximal median or anterior cerebral arteries. This pattern of arterial occlusion leads to the formation of extensive arterial collaterals at the base of the cerebrum. 81 Digital subtraction angiography or MR angiography shows occlusion of the distal internal carotid arteries and collateral circulation or stenosis of the intracerebral arteries. 126 Ischaemic stroke in MIDs has rarely been reported in KSS. 127 Only in single cases has Moyamoya disease been described in patients with paediatric MIDs. 80, 128 7.6.2 Hypophyseal abnormalities. Rarely, there is involvement of the pituitary gland in the cerebral degeneration of paediatric MIDs. In case the pituitary gland is affected, hypopituitarism or morphological abnormalities of the pituitary gland on imaging studies may be visible. This is particularly the case with pituitary adenomas, which may require surgical intervention after becoming symptomatic. Another morphological abnormality associated with hypopituitarism is the 'empty sella'. 113, 129 Though endocrine abnormalities may occur in many of the MIDs, they are particularly found in patients with MELAS, 130 LS, 131 or KSS. 132 In a 5-year-old boy with non-specific MIMODS associated with a complex-II defect, growth hormone deficiency was diagnosed at age 6 months and growth hormone substitution initiated. 133 Growth hormonesecreting pituitary adenomas have also been reported in patients with MID due to SDH mutations. 134 7.6.3 Hypo-/hypermetabolism, receptor densities. PET studies have been only rarely applied in the diagnostic work-up of CNS involvement of MIDs. In a study of patients (one patient was aged 10 years) carrying POLG1 mutations, loss of dopaminergic neurons was demonstrated by PET. 135 PET studies in eight carriers of the m.3243A>G mtDNA mutation (one patient was 15 years old and one 18 years old) showed widespread cortical and basal ganglia metabolic deficits. 136 In patients with LS fludeoxyglucose-PET studies revealed hypometabolism of the temporal lobe, basal ganglia, or cerebellum. 137 In a girl with NARP due to the mutation m.8729G>A, 99 mT-SPECT revealed hypoperfusion of the brainstem and the cerebellum. 18 7.6.4 Cerebral bleeding. Cerebral bleeding has been reported only rarely in paediatric MID patients. In the acute stage of an SLL, extensive petechial haemorrhage along the gyri of the cortex has been reported. 138 Additionally, there are reports describing intracortical bleeding in the acute stage of an SLL. 33 Focal cortical haemorrhage has been found at autopsy in a child with MELAS and SLLs in the chronic stage. 139 In an adolescent patient with mitochondrial encephalomyopathy cerebral haemorrhage was fatal. 140 In a study of seven patients with nonspecific mitochondrial encephalomyopathy, one of them experienced putaminal haemorrhage. 141 7.6.5 Cysts/lacunas. Intra-cerebral cysts may develop after lacunar stroke, within WMLs, or in association with neuromigrational abnormalities. 31, 142 Cystic cerebral lesions visible on CCT or MRI were particularly reported in patients with MELAS, MERRF, and LS. Lacunas in the basal ganglia are also a frequent feature of specific or non-specific MIMODS. 143 Mutations in the RMND1 gene, encoding a protein involved in mitochondrial translation, typically manifests phenotypically as leucoencephalopathy with temporal lobe cysts. 143 31 or spongyform changes of the brainstem or cerebellum. 83 Congenital cerebral malformations are also a frequent finding in the French-Canadian type of LS due to LRPPRC mutations. 148 Whether these cerebral malformations are due to chromosomal defects in addition to their mutations responsible for MID, remains speculative.
7.6.7 Others. The eye-of-the-tiger sign of the globus pallidus has been reported in patients with neurodegeneration with brain iron accumulation or mitochondrial membrane protein-associated neurodegeneration due to mutations in C10orf12.
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In patients with GRACILE-syndrome due to mutations in BCS1L, the cerebral cortex showed a specific pattern of astrogliosis and widespread loss of microglia. 150 Single mtDNA deletions may manifest as MIMODS with onset from infancy to adulthood. 151 Cerebral imaging in these patients may reveal a hot-cross bun sign, thus mimicking multiple system atrophy of the cerebellar subtype. 151 
Discussion
This review shows that there are a number of cerebral and spinal abnormalities in paediatric patients with a MID. The most frequent of the cerebral abnormalities on imaging are WMLs, GMLs, SLLs, atrophy, calcifications, optic atrophy, and abnormal functional studies. Cerebral abnormalities on imaging occur not only in specific MIDs but also in non-specific MIMODS. Usually, these CNS lesions accompany clinical abnormalities but in rare cases cerebral lesions in MIDs may be asymptomatic. Concerning the outcome of these lesions, they may generally resolve completely or may remain over a short or long period of time, without resolution ever. Imaging modalities applied to detect and monitor CNS lesions in paediatric MIDs are ultrasound, CT, MRI/MRS, SPECT, and PET. Each of these techniques has its strengths and limitations. The most valuable modality at present, however, is the MRI. Cerebral imaging in paediatric MIDs may help to exclude various differentials and to establish the correct diagnosis. WMLs need to be differentiated from lesions typically found in multiple sclerosis and SLLs need to be differentiated from ischaemic stroke. This can be challenging since SLLs and ischaemic lesions may coexist and may be difficult to distinguish. Helpful to accomplish this task could be a detailed individual and family history, a thorough clinical exam also assessing atypical phenotypic features, and the application of an appropriate instrumental diagnostic work-up. Differentiation between ischaemic and metabolic lesions is crucial because options for treatment are completely different. Whereas ischaemic lesions require drugs for secondary prophylaxis and drugs given to achieve symptomatic relief in these patients, MID patients with an SLL require multiprofessional management, including application of L-arginine or citrulline. Of additional help could be antiepileptic treatment because SLLs are frequently accompanied by epileptic discharges or even symptomatic seizures in these patients. Future research should be directed toward the appropriate identification of cerebral lesions in paediatric MIDs. Of particular interest should be SLLs, their pathogenesis and dynamics with disease progression, and the influence of treatment. Identification of specific metabolites in the cerebrospinal fluid by MRS could serve as biomarkers for diagnosing the disease and for assessing the reaction to treatment.
Summary
The brain is frequently affected in MIDs. CNS lesions in paediatric patients with an MID need to be recognised and put into context. Cerebral imaging is the key investigation to diagnose and monitor paediatric MIDs with CNS involvement. CNS imaging should be carried out in paediatric MID patients even if they do not present with clinical CNS manifestations. Prospective imaging studies need to be carried out in asymptomatic patients not only to correctly identify the lesion of interest but also to monitor its alterations over time. Despite the accuracy of imaging there is a need to diagnose MIDs by means other than imaging, particularly biochemical and genetic investigations. Imaging cannot replace a thorough search for a possible mitochondrial background of a disease but will supplement the effort to reach the correct diagnosis by other means. 
